Use of bone-modifying agents among breast cancer patients with bone metastasis: evidence from oncology practices in the US

References

• SiegelRLMillerKDJemalACancer statistics, 2018CA Cancer J Clin201868173029313949
   PubMed Web of Science ®Google Scholar
• LiSPengYWeinhandlEDEstimated number of prevalent cases of metastatic bone disease in the US adult populationClin Epidemiol20124879322570568
   PubMedGoogle Scholar
• ZhangHZhuWBiskupEIncidence, risk factors and prognostic characteristics of bone metastases and skeletal-related events (SREs) in breast cancer patients: A systematic review of the real world dataJ Bone Oncol201811385029511626
   PubMed Web of Science ®Google Scholar
• LiedeAJerzakKJHernandezRKWadeSWSunPNarodSAThe incidence of bone metastasis after early-stage breast cancer in CanadaBreast Cancer Res Treat2016156358759527083181
   PubMed Web of Science ®Google Scholar
• HernandezRKWadeSWReichAPirolliMLiedeALymanGHIncidence of bone metastases in patients with solid tumors: analysis of oncology electronic medical records in the United StatesBMC Cancer20181814429306325
   PubMed Web of Science ®Google Scholar
• ColemanREClinical features of metastatic bone disease and risk of skeletal morbidityClin Cancer Res20061220 Pt 26243s624917062708
   PubMed Web of Science ®Google Scholar
• WardleyADavidsonNBarrett-LeePZoledronic acid significantly improves pain scores and quality of life in breast cancer patients with bone metastases: a randomised, crossover study of community vs hospital bisphosphonate administrationBr J Cancer200592101869187615870721
   PubMed Web of Science ®Google Scholar
• SathiakumarNDelzellEMorriseyMAMortality following bone metastasis and skeletal-related events among women with breast cancer: a population-based analysis of U.S. Medicare beneficiaries, 1999–2006Breast Cancer Res Treat2012131123123821842243
   PubMed Web of Science ®Google Scholar
• HagiwaraMDeleaTEChungKHealthcare costs associated with skeletal-related events in breast cancer patients with bone metastasesJ Med Econ201417322323024494707
   PubMedGoogle Scholar
• JensenAØJacobsenJBNørgaardMYongMFryzekJPSørensenHTIncidence of bone metastases and skeletal-related events in breast cancer patients: a population-based cohort study in DenmarkBMC Cancer2011112921261987
   PubMed Web of Science ®Google Scholar
• Pamidronate Disodium [prescribing information]Bedford, OHBedford Laboratories2014 Available from: https://www.accessdata.fda.gov/drug-satfda_docs/label/2014/021113s017lbl.pdfAccessed August 27, 2018
   Google Scholar
• Zometa [prescribing information]East Hanover, NJNovartis Pharmaceuticals Corporation2016 Available from: https://www.pharma.us.novartis.com/sites/www.pharma.us.novartis.com/files/Zometa.pdfAccessed August 27, 2018
   Google Scholar
• XGEVA [prescribing information]Thousand Oaks, CAAmgen Inc2017 Available from: http://pi.amgen.com/~/media/amgen/repository-sites/pi-amgen-com/xgeva/xgeva_pi.ashxAccessed August 27, 2018
   Google Scholar
• WongMHStocklerMRPavlakisNBisphosphonates and other bone agents for breast cancerCochrane Database Syst Rev20122Cd003474
   Google Scholar
• FordJAJonesREldersADenosumab for treatment of bone metastases secondary to solid tumours: systematic review and network meta-analysisEur J Cancer201349241643022906748
   PubMed Web of Science ®Google Scholar
• HatoumHTLinSJSmithMRBarghoutVLiptonAZoledronic acid and skeletal complications in patients with solid tumors and bone metastases: analysis of a national medical claims databaseCancer200811361438144518720527
   PubMed Web of Science ®Google Scholar
• HatoumHTLinSJSmithMRGuoALiptonATreatment persistence with monthly zoledronic acid is associated with lower risk and frequency of skeletal complications in patients with breast cancer and bone metastasisClin Breast Cancer201111317718321665138
   PubMed Web of Science ®Google Scholar
• van PoznakCHTeminSYeeGCAmerican Society of Clinical Oncology executive summary of the clinical practice guideline update on the role of bone-modifying agents in metastatic breast cancerJ Clin Oncol20112991221122721343561
   PubMed Web of Science ®Google Scholar
• GralowJRBiermannJSFarookiANCCN Task Force Report: Bone Health In Cancer CareJ Natl Compr Canc Netw201311Suppl 3S150 quiz S51
   PubMed Web of Science ®Google Scholar
• Flatiron Health Available from: https://flatiron.com/real-world-evidence/Accessed August 27, 2018
   Google Scholar
• LiedeAHernandezRKRothMCalkinsGLarrabeeKNicacioLValidation of International Classification of Diseases coding for bone metastases in electronic health records using technology-enabled abstractionClin Epidemiol2015744144826635485
   PubMed Web of Science ®Google Scholar
• LeveyASStevensLASchmidCHA new equation to estimate glomerular filtration rateAnn Intern Med2009150960461219414839
   PubMed Web of Science ®Google Scholar
• FineJPGrayRJA Proportional Hazards Model for the Subdistribution of a Competing RiskJ Am Stat Assoc199994446496509
   Web of Science ®Google Scholar
• R: A Language and Environment for Statistical Computing [computer program]ViennaR Foundation for Statistical Computing2017
   Google Scholar
• HernandezRKAdhiaAWadeSWPrevalence of bone metastases and bone-targeting agent use among solid tumor patients in the United StatesClin Epidemiol2015733534526229504
   PubMed Web of Science ®Google Scholar
• QianYBhowmikDKachruNHernandezRKLongitudinal patterns of bone-targeted agent use among patients with solid tumors and bone metastases in the United StatesSupport Care Cancer20172561845185128120114
   PubMed Web of Science ®Google Scholar
• SchroderJFietzTKohlerATreatment and pattern of bone metastases in 1094 patients with advanced breast cancer - Results from the prospective German Tumour Registry Breast Cancer cohort studyEur J Cancer20177913914828494404
   PubMed Web of Science ®Google Scholar
• ButlerAMCetinKHernandezRKTreatment dynamics of bone-targeting agents among men with bone metastases from prostate cancer in the United StatesPharmacoepidemiol Drug Saf201827222923829316026
   PubMed Web of Science ®Google Scholar
• EakerSDickmanPWBergkvistLHolmbergLUppsala/Orebro Breast Cancer GroupDifferences in management of older women influence breast cancer survival: results from a population-based database in SwedenPLoS Med200633e2516409108
   PubMed Web of Science ®Google Scholar
• EngerSMThwinSSBuistDSBreast cancer treatment of older women in integrated health care settingsJ Clin Oncol200624274377438316983106
   PubMed Web of Science ®Google Scholar
• BouchardyCRapitiEBlagojevicSVlastosATVlastosGOlder female cancer patients: importance, causes, and consequences of undertreatmentJ Clin Oncol200725141858186917488984
   PubMed Web of Science ®Google Scholar
• SheppardVBFaulLALutaGFrailty and adherence to adjuvant hormonal therapy in older women with breast cancer: CALGB protocol 369901J Clin Oncol201432222318232724934786
   PubMed Web of Science ®Google Scholar
• BursteinHJThe distinctive nature of HER2-positive breast cancersN Engl J Med2005353161652165416236735
   PubMed Web of Science ®Google Scholar
• GlynnRJKnightELLevinRAvornJParadoxical relations of drug treatment with mortality in older personsEpidemiology200112668268911679797
   PubMed Web of Science ®Google Scholar
• RedelmeierDATanSHBoothGLThe treatment of unrelated disorders in patients with chronic medical diseasesN Engl J Med199833821151615209593791
   PubMed Web of Science ®Google Scholar
• JacksonLANelsonJCBensonPFunctional status is a confounder of the association of influenza vaccine and risk of all cause mortality in seniorsInt J Epidemiol200635234535216368724
   PubMed Web of Science ®Google Scholar
• AmadoriDAgliettaMAlessiBEfficacy and safety of 12-weekly versus 4-weekly zoledronic acid for prolonged treatment of patients with bone metastases from breast cancer (ZOOM): a phase 3, open-label, randomised, non-inferiority trialLancet Oncol201314766367023684411
   PubMed Web of Science ®Google Scholar
• HimelsteinALFosterJCKhatcheressianJLEffect of Longer-Interval vs Standard Dosing of Zoledronic Acid on Skeletal Events in Patients With Bone Metastases: A Randomized Clinical TrialJAMA20173171485828030702
   PubMed Web of Science ®Google Scholar
• van PoznakCSomerfieldMRBarlowWERole of Bone-Modifying Agents in Metastatic Breast Cancer: An American Society of Clinical Oncology-Cancer Care Ontario Focused Guideline UpdateJ Clin Oncol201735353978398629035643
   PubMed Web of Science ®Google Scholar
• MenshawyAMattarOAbdulkarimADenosumab versus bisphosphonates in patients with advanced cancers-related bone metastasis: systematic review and meta-analysis of randomized controlled trialsSupport Care Cancer20182641029103829387997
   PubMed Web of Science ®Google Scholar
• StopeckATFizaziKBodyJJSafety of long-term denosumab therapy: results from the open label extension phase of two phase 3 studies in patients with metastatic breast and prostate cancerSupport Care Cancer201624144745526335402
   PubMed Web of Science ®Google Scholar
• StopeckATLiptonABodyJJDenosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind studyJ Clin Oncol201028355132513921060033
   PubMed Web of Science ®Google Scholar
• RuggieroSLDodsonTBFantasiaJAmerican Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw-2014 updateJ Oral Maxillofac Surg201472101938195625234529
   PubMed Web of Science ®Google Scholar
• KhanAAMorrisonAHanleyDADiagnosis and management of osteonecrosis of the jaw: a systematic review and international consensusJ Bone Miner Res201530132325414052
   PubMed Web of Science ®Google Scholar